Tomomitsu Hotta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomomitsu Hotta has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Kiyoshi Ando
Department of Hematology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan
2 shared publications Shunichi Kato
2 shared publicationsAyako Higuchi
1 shared publicationBalgansuren Gansuvd
1 shared publicationChie Nakashioya
1 shared publication- Fumi Mizoroki
Division of Hematology and Oncology, Daisan Hospital, Jikei University School of Medicine, Komaeshi, Tokyo 201-8601, Japan
1 shared publication
Latest Publications
- Open Access
- 19 January 2011
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 41 (4) , 586-589
Melphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112
A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau. Between November 2002 and November 2005, 34 patients were registered. The study was closed early because of poor accrual. Thirty-three eligible patients, with a median age of 65 years (range: 47-77 years) were analyzed for the secondary purpose. For induction therapy, 16 patients were treated with vincristine-doxorubicin-dexamethasone and 17 with melphalan-prednisolone initially. In eight cases, induction therapy was switched because of a poor response. Both regimens were well tolerated, but neutropenia, anorexia, constipation and infection with neutropenia were more frequent for vincristine-doxorubicin-dexamethasone. Best response rates were 44% (95% confidence interval, 20-70) and 47% (95% confidence interval, 23-72), respectively, for vincristine-doxorubicin-dexamethasone and melphalan-prednisolone. Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma.
- 19 January 2011
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 41 (4) , 586-589
Open AccessMelphalan-Prednisolone and Vincristine-Doxorubicin-Dexamethasone Chemotherapy followed by Prednisolone/Interferon Maintenance Therapy for Multiple Myeloma: Japan Clinical Oncology Group Study, JCOG0112
A multicenter phase III study for untreated multiple myeloma was conducted to investigate a switch-induction chemotherapy with melphalan-prednisolone and vincristine-doxorubicin-dexamethasone followed by randomization on maintenance therapy for patients achieving plateau. Between November 2002 and November 2005, 34 patients were registered. The study was closed early because of poor accrual. Thirty-three eligible patients, with a median age of 65 years (range: 47-77 years) were analyzed for the secondary purpose. For induction therapy, 16 patients were treated with vincristine-doxorubicin-dexamethasone and 17 with melphalan-prednisolone initially. In eight cases, induction therapy was switched because of a poor response. Both regimens were well tolerated, but neutropenia, anorexia, constipation and infection with neutropenia were more frequent for vincristine-doxorubicin-dexamethasone. Best response rates were 44% (95% confidence interval, 20-70) and 47% (95% confidence interval, 23-72), respectively, for vincristine-doxorubicin-dexamethasone and melphalan-prednisolone. Vincristine-doxorubicin-dexamethasone/melphalan-prednisolone switch-induction therapy might be feasible and effective for Japanese patients with multiple myeloma.
- 1 September 2004
- Vol. 45 (9) , 1048-52
[Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer].
Despite the promising outcomes of unrelated cord blood transplantations (UCBT) in pediatric recipients, the major limitation in the widespread use of cord blood (CB) as a source of hematopoietic stem cells (HSC), particularly in adults, is the physiological small number of cells. To overcome this limitation, we developed an ex vivo expansion system for HSC, in which CB CD34+ cells are cultured on feeder cells (HESS-5 cells) in the presence of cytokines (TPO, SCF and Flt3 ligand). A phase I/II clinical trial, approved by our institutional review board, has been started to assess the safety and effectiveness of this system. A 52-year-old woman with metastatic breast cancer and myelodysplastic syndrome (MDS) received a non-myeloablative preparative regimen followed by UCBT. On day 0, 75% of the whole CB and a fraction of CD34 negative cells were transplanted. The remaining 25% of the CB was CD34-selected and expanded on HESS-5 in a non-serum media in the presence of TPO, SCF, and Flt3-L. On day 5, the ex vivo-expanded, CD34+ cells were transplanted. The patient received 1.83 x 10(7)/kg of total nucleated cells and 7.7 X 10(4)/kg of CD34+ cells (expanded and unexpanded). No acute adverse effects were observed after the infusion of the cultured cells. She suffered from pneumonia on day 37, a cerebral hemorrhage on day 48, and died on day 50. Further studies are required to assess the effectiveness of this protocol.
- 1 September 2004
- Vol. 45 (9) , 1048-52
[Cord blood transplantation supported with ex vivo expanded fraction for a patient with myelodysplastic syndrome and metastatic breast cancer].
Despite the promising outcomes of unrelated cord blood transplantations (UCBT) in pediatric recipients, the major limitation in the widespread use of cord blood (CB) as a source of hematopoietic stem cells (HSC), particularly in adults, is the physiological small number of cells. To overcome this limitation, we developed an ex vivo expansion system for HSC, in which CB CD34+ cells are cultured on feeder cells (HESS-5 cells) in the presence of cytokines (TPO, SCF and Flt3 ligand). A phase I/II clinical trial, approved by our institutional review board, has been started to assess the safety and effectiveness of this system. A 52-year-old woman with metastatic breast cancer and myelodysplastic syndrome (MDS) received a non-myeloablative preparative regimen followed by UCBT. On day 0, 75% of the whole CB and a fraction of CD34 negative cells were transplanted. The remaining 25% of the CB was CD34-selected and expanded on HESS-5 in a non-serum media in the presence of TPO, SCF, and Flt3-L. On day 5, the ex vivo-expanded, CD34+ cells were transplanted. The patient received 1.83 x 10(7)/kg of total nucleated cells and 7.7 X 10(4)/kg of CD34+ cells (expanded and unexpanded). No acute adverse effects were observed after the infusion of the cultured cells. She suffered from pneumonia on day 37, a cerebral hemorrhage on day 48, and died on day 50. Further studies are required to assess the effectiveness of this protocol.
- 1 April 2003
- Vol. 28 (1) , 1-7
Comparison of soluble and membrane bound HLA-class I and DR levels in umbilical cord blood and adult peripheral blood.
HLAs are membrane bound (membrane HLA mHLA) or secreted as soluble forms(soluble HLA = sHLA) in plasma or serum. Umbilical cord blood (UCB) mHLA, from mononuclear cells (MNCs), and sHLA were quantified by flow cytometry and enzyme linked immunosorbant assay (ELISA), respectively, and compared to levels of MNC-mHLA and sHLA in adult peripheral blood (PB). The mean fluorescence intensity (MFI) of mHLA-I was 3-fold lower in UCB-MNCs than in adult PB-MNCs, however, due to higher cell numbers in UCB, total mHLA-I quantities per ml of blood were not different in UCB and adult PB. In addition, sHLA-I in UCB was significantly lower than in adult PB. The MFI of mHLA-DR from UCB-MNCs was significantly higher than the MFI of mHLA-DR in adult PB-MNCs, and the total mDR quantity (per ml of blood) in UCB was 3-fold higher than in adult PB. sHLA-DR concentrations, however, were equivalent in UCB and adult PB. These findings indicate that fetal tissue or cells might excrete smaller quantities of both sHLA-I and sDR antigens than adult tissues or cells. Alternatively, fetal sHLA antigens might be unstable and degradated compared to those of adult.
- 1 April 2003
- Vol. 28 (1) , 1-7
Comparison of soluble and membrane bound HLA-class I and DR levels in umbilical cord blood and adult peripheral blood.
HLAs are membrane bound (membrane HLA mHLA) or secreted as soluble forms(soluble HLA = sHLA) in plasma or serum. Umbilical cord blood (UCB) mHLA, from mononuclear cells (MNCs), and sHLA were quantified by flow cytometry and enzyme linked immunosorbant assay (ELISA), respectively, and compared to levels of MNC-mHLA and sHLA in adult peripheral blood (PB). The mean fluorescence intensity (MFI) of mHLA-I was 3-fold lower in UCB-MNCs than in adult PB-MNCs, however, due to higher cell numbers in UCB, total mHLA-I quantities per ml of blood were not different in UCB and adult PB. In addition, sHLA-I in UCB was significantly lower than in adult PB. The MFI of mHLA-DR from UCB-MNCs was significantly higher than the MFI of mHLA-DR in adult PB-MNCs, and the total mDR quantity (per ml of blood) in UCB was 3-fold higher than in adult PB. sHLA-DR concentrations, however, were equivalent in UCB and adult PB. These findings indicate that fetal tissue or cells might excrete smaller quantities of both sHLA-I and sDR antigens than adult tissues or cells. Alternatively, fetal sHLA antigens might be unstable and degradated compared to those of adult.
- Open Access
- 27 October 1999
- Published by Wiley in American Journal of Hematology
- Vol. 62 (3) , 159-164
Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia
- 27 October 1999
- Published by Wiley in American Journal of Hematology
- Vol. 62 (3) , 159-164
Open AccessAltered expression of CD45 isoforms in differentiation of acute myeloid leukemia